- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
December 2016
November 2016
Phase 1 Study of CB-839, a Small Molecule Inhibitor of Glutaminase, In Combination with Everolimus in Patients with Clear Cell and Papillary Renal Cell Carcinoma CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitorsNCI AACR EORTC – 2016
November 2016
November 2016
Arginase Inhibitor CB-1158 Alleviates Immunosuppression And Enhances Anti-Tumor Responses As A Single Agent And In Combination With Other Immunotherapies CX-1158-101: A First-in-Human Phase 1 Study of a Small Molecule Inhibitor of Arginase (CB-1158) as Monotherapy and in Combination with an anti-PD-1 Checkpoint Inhibitor in Patients with Solid TumorsSociety for Immunotherapy of Cancer
November 2016
Targeting Tumor Glutamine Metabolism with CB‐839 Enhances the Efficacy of Immune Checkpoint Inhibitors CX-839-004: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid TumorsSociety for Immunotherapy of Cancer
Our Pipeline
We are focused on solid tumors for
which new treatments are urgently needed.